[ET Net News Agency, 3 August 2021] SINO BIOPHARM (01177) rose 2.54% to HK$6.86,
breaking above the 10-D SMA of HK$6.73.
It hits an intra-day high of HK$6.91, and an intra-day low of HK$6.64. The total shares
traded was 11.58 million, with a value of HK$78.33m. The active buy/sell ratio is 76:24,
with net buying turnover of HK$33.72m. J.P. MORGAN BRO (HK) accounts for greatest net
responsive buying turnover of HK$1.23m, with volume weighted average price of HK$6.793.
CLSA LTD accounts for greatest net responsive selling turnover of HK$5.74m, with volume
weighted average price of HK$6.774. The stock has risen a combined 3.94% over the past 2
consecutive trading days.
The Hang Seng Index now fell 327 points, or 1.25% to 25,908; the Hang Seng China
Enterprises Index now fell 119 points, or 1.28% to 9,216; the Hang Seng TECH Index now
fell 146 points, or 2.15% to 6,650; with an overall turnover of HK$49.35b.
The SSE Composite Index now fell 24 points, or 0.71% to 3,439, with an overall turnover
of RMB171.94b.
The SZSE Component Index now fell 117 points, or 0.8% to 14,680, with an overall
turnover of RMB122.79b.
Basic Information
-------------------------------------------
Nominal 6.860 % Chg +2.54%
High 6.910 Low 6.640
Shares Tr 11.58m Turnover 78.33m
10-D SMA 6.730 %H.V 33.778
20-D SMA 6.910 VWAP 6.764
50-D SMA 7.653 RSI14 43.255
-------------------------------------------
Status: Breaking above the 10-D SMA, active buy/sell ratio is 76:24, with net buying
turnover of HK$33.72m, rising a combined 3.94% over the past 2 consecutive
trading days
Table: Performance of stocks in the same sector or of relevance
Stock (Code) Price(HK$) Change(%)
-------------------------------------------------
SINO BIOPHARM (01177) 6.86 +2.54
SIHUAN PHARM (00460) 2.77 +1.47
CSPC PHARMA (01093) 10.68 +1.91
3SBIO (01530) 6.56 -0.91
SIMCERE PHARMA (02096) 9.29 -0.32
FOSUN PHARMA (02196) 72.25 +2.34
WUXI APPTEC (02359) 175.40 +1.86
HANSOH PHARMA (03692) 27.50 -0.36
PHARMARON (03759) 174.20 +1.22
HEPALINK (09989) 10.46 +9.64
-------------------------------------------------
(ed)